Literature DB >> 28051259

MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6.

Y Li1, J Liu, Z-Z Liu, W-B Wei.   

Abstract

OBJECTIVE: Osteosarcoma (OS) is reported to be one of the most familiar forms of the primary malignant tumor to adolescents and adults, which is usually found in their long bones. Evidence and data have shown that abnormality in micro-RNA expression is closely related to tumorigenesis. The aim of this study is to investigate the expression, function and underlying mechanism of miR-145 in OS.
MATERIALS AND METHODS: MiR-145 expression in tumor tissues of patients and cell lines were detected by SYBR green qPCR. Kaplan-Meier method and log-rank test were applied to analyze the overall survival of patients with different miR-145 expression. MG-63 and U2OS cells were transfected with miR-145 or miR-NC, after which we recorded and analyzed the proliferation, migration and invasion respectively. Potential binding sites of miR-145 in CDK6 was identified using TargetScan 6.2. Meanwhile, OS cells were transfected with miR-NC, miR-145, or transfected with miR-145 and CDK6 vector together to find out whether the effect of miR-145 inhibit growth and mobility of OS cells were via targeting CDK6. Moreover, the expression of miR-145 was mediated by a constructed lentivirus vector to inoculate nude mice to observe the inhibiting effect of miR-145 in OS in vivo.
RESULTS: MiR-145 downregulation was remarkably related with the occurrence of a phenotype of OS with more aggressiveness. The univariate analysis was applied which showed that with a lower miR-145 level in OS patients led to a more unfavorable prognosis, or, a lower overall survival rate. In OS cells, cell proliferation, motility and invasion were inhibited by ectopic overexpression of miR-145 in vitro. Further studies into the mechanism indicated that its expression probably has a close interrelationship with the 3'- untranslated region (3'-UTR) of CDK6 mRNA, whose mRNA and expression levels were inhibited. And it is found that CDK6 expression was also reversely related to miR-145 expression in clinical specimens. In in vivo experiment, the miR-145 inhibits the growth of OS tumor.
CONCLUSIONS: miR-145 plays a crucial role in inhibiting invasive and metastatic of OS, whose underlying mechanism probably is directly targeting CDK6. Therefore, MiR-145 is believed to have an important role in growth and metastasis of OS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28051259

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

Review 3.  MiR-145: a potential biomarker of cancer migration and invasion.

Authors:  Wen-Xiu Xu; Zhen Liu; Fei Deng; Dan-Dan Wang; Xing-Wang Li; Tian Tian; Jian Zhang; Jin-Hai Tang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

Review 4.  The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease.

Authors:  Catarina Melim; Ivana Jarak; Francisco Veiga; Ana Figueiras
Journal:  3 Biotech       Date:  2020-03-02       Impact factor: 2.406

5.  Association of ERCC gene polymorphism with osteosarcoma risk.

Authors:  Guanliang Wang; Jianping Li; Xiling Xu; Ramit Kumar Gupta; Xiaoqiang Gao
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

6.  miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma.

Authors:  Wei Yuan; Du Wang; Yang Liu; Dongdong Tian; Yang Wang; Ranxi Zhang; Liangjun Yin; Zhongliang Deng
Journal:  Mol Med Rep       Date:  2017-10-04       Impact factor: 2.952

7.  MiR-145 inhibits the epithelial-to-mesenchymal transition via targeting ADAM19 in human glioblastoma.

Authors:  Xingqiang Wang; Enqin Wang; Jun Cao; Feng Xiong; Yonglin Yang; Haitao Liu
Journal:  Oncotarget       Date:  2017-09-30

8.  Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma.

Authors:  Demeng Chen; Zhiqiang Zhao; Zixin Huang; Du-Chu Chen; Xin-Xing Zhu; Yi-Ze Wang; Ya-Wei Yan; Shaojun Tang; Subha Madhavan; Weiyi Ni; Zhan-Peng Huang; Wen Li; Weidong Ji; Huangxuan Shen; Shuibin Lin; Yi-Zhou Jiang
Journal:  Bone Res       Date:  2018-04-04       Impact factor: 13.567

Review 9.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.